DR. REDDY'S LABORATORIES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 78.47 USD | -2.45% |
|
+1.02% | +12.78% |
| Sales 2025 * | 302B 3.62B | Sales 2026 * | 325B 3.89B | Capitalization | 1,106B 13.25B |
|---|---|---|---|---|---|
| Net income 2025 * | 55.13B 660M | Net income 2026 * | 56.89B 681M | EV / Sales 2025 * | 3.36 x |
| Net cash position 2025 * | 88.77B 1.06B | Net cash position 2026 * | 124B 1.48B | EV / Sales 2026 * | 3.02 x |
| P/E ratio 2025 * |
20
x | P/E ratio 2026 * |
19.4
x | Employees | 27,048 |
| Yield 2025 * |
0.6% | Yield 2026 * |
0.61% | Free-Float | 70.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on Dr. Reddy's Laboratories Limited
More recommendations
More press releases
More news
| 1 day | -2.45% | ||
| 1 week | +1.02% | ||
| Current month | +2.99% | ||
| 1 month | +9.21% | ||
| 3 months | +9.58% | ||
| 6 months | +13.84% | ||
| Current year | +12.78% |
1 week
77.94
80.79
1 month
70.5280.79
Current year
67.1680.79
1 year
62.6880.79
3 years
47.8880.79
5 years
33.3380.79
10 years
28.1380.79
| Managers | Title | Age | Since |
|---|---|---|---|
Erez Israeli
CEO | Chief Executive Officer | 57 | 18-04-01 |
Parag Agarwal
DFI | Director of Finance/CFO | - | 20-11-01 |
| Chairman | 56 | 93-01-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gunupati Prasad
CHM | Chairman | 63 | 86-04-07 |
| Chairman | 56 | 93-01-17 | |
Kalpana Morparia
BRD | Director/Board Member | 74 | 07-06-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.69% | 96 M€ | -.--% | - | |
| 1.76% | 11 M€ | -.--% | - | |
| 0.56% | 21 M€ | +11.03% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-16 | 78.47 | -2.45% | 568,965 |
| 24-07-15 | 80.44 | +1.07% | 389,584 |
| 24-07-12 | 79.59 | +1.08% | 252,942 |
| 24-07-11 | 78.74 | +0.66% | 202,266 |
| 24-07-10 | 78.22 | +0.70% | 228,326 |
Delayed Quote Nyse, July 16, 2024 at 04:00 pm EDT
More quotes
Dr. Reddy's Laboratories specializes in developing, producing, and selling pharmaceutical products. Net sales break down by activity as follows:
- sales of generic medications (79.9%): brand-name or generic prescription medications and OTC medicines;
- sales of active ingredients (15.7%). The group also supplies customized pharmaceutical services;
- other (4.4%): sales of generic biopharmaceutical products, development of molecular agents, etc.
Net sales are distributed geographically as follows: India (18.8%), the United States (45%), Russia (9.9%) and other (26.3%).
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q1 2025 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
6,643
INR
Average target price
6,164
INR
Spread / Average Target
-7.21%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +61.53% | 848B | |
| +32.47% | 627B | |
| -3.66% | 363B | |
| +15.06% | 318B | |
| +9.18% | 299B | |
| +12.68% | 234B | |
| +16.37% | 225B | |
| +15.67% | 179B | |
| +2.47% | 167B |
- Stock Market
- Equities
- DRREDDY Stock
- RDY Stock
